Psoriasis and atopic dermatitis are prevalent autoimmune skin conditions that significantly impact patient quality of life. Current management strategies often struggle with persistent pruritus and frequent relapses after therapy ends. However, a recent study introduces a transformative inflammatory dermatosis treatment using AC@Mg/Ce-UiO nanozymes. This dual-catalytic approach targets the molecular roots of skin inflammation to ensure long-term remission.

The progression of these dermatoses is driven by a critical chemical imbalance. Specifically, pro-inflammatory adenosine triphosphate (ATP) levels rise while anti-inflammatory cyclic adenosine monophosphate (cAMP) levels fall. Moreover, the accumulation of reactive oxygen species (ROS) further damages the skin barrier. Consequently, addressing these three factors simultaneously is essential for effective disease control.

Mechanism of AC@Mg/Ce-UiO in Inflammatory Dermatosis Treatment

Researchers developed the AC@Mg/Ce-UiO nanozyme to integrate adenylate cyclase (AC) with a defect-engineered magnesium-cerium framework. This unique structure provides enhanced superoxide dismutase-like and catalase-like activities. Furthermore, it facilitates efficient ROS scavenging within the skin lesions. Additionally, the encapsulated AC enzyme catalyzes the direct conversion of excess ATP into anti-inflammatory cAMP.

In vivo studies demonstrate that this therapy markedly downregulates inflammatory cytokines and pruritogens. It also inhibits keratinocyte hyperproliferation and reduces the infiltration of immune memory T cells. Therefore, the nanozyme not only clears active symptoms like lesions and itching but also decreases the likelihood of future recurrence. This safe and potent therapy offers a promising alternative to traditional immunosuppressants.

Frequently Asked Questions

How does the AC@Mg/Ce-UiO nanozyme prevent disease recurrence?

The nanozyme reduces the infiltration of immune memory T cells and restores the ATP/cAMP balance. Consequently, this stabilizes the skin microenvironment and prevents the inflammatory flares that typically follow treatment cessation.

What makes this approach better than traditional steroids?

Standard steroids often lead to side effects and rapid relapse. In contrast, this nanozyme targets the fundamental pathogenesis by scavenging reactive oxygen species and correcting nucleotide imbalances, offering a safer profile for long-term remission.

Disclaimer: This content is for informational and educational purposes only. It does not constitute professional medical advice, diagnosis, or treatment. Always seek the advice of your physician or other qualified health provider with any questions you may have regarding a medical condition. Refer to the latest local and national guidelines for clinical practice.

References

Su X et al. Nanozymes for ATP/cAMP balance restoration and ROS scavenging in inflammatory dermatosis treatment and recurrence prevention. J Nanobiotechnology. 2026 Feb 10. doi: 10.1186/s12951-026-04130-w. PMID: 41668176.